SLDB
Solid Biosciences LLC
NASDAQ: SLDB · HEALTHCARE · BIOTECHNOLOGY
$7.68
+5.69% today
Updated 2026-06-04
Market cap
$817.13M
P/E ratio
—
P/S ratio
3.65x
EPS (TTM)
$-1.92
Dividend yield
—
52W range
$4 – $9
Volume
1.8M
WallStSmart proprietary scores
31
out of 100
Grade: F
Strong Sell
Investment rating
3.7
Growth
D6.5
Quality
B3.0
Profitability
D5.0
Valuation
C+2/9
Piotroski F-Score
Weak
-5.3
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →203 stocks currently score above 75
Price targets
Analyst target
$17.38
+126.30%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
4 Strong Buy10 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Debt/equity 0.06x — low leverage
Risks
- Piotroski 2/9 — weak financial health
- Altman Z -5.30 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-47.40M
- Revenue declining -100.00% QoQ
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $8.09M | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-85.98M | $-96.02M | $-124.70M | $-174.32M | $-56.74M |
| EPS | — | — | — | — | $-1.92 |
| Free cash flow | $-100.99M | $-95.69M | $-100.67M | $-157.44M | $-47.40M |
| Profit margin | -1,062.28% | — | — | — | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-02 | SMITH, IAN F | Sale | 3,441 | — |
| 2026-04-02 | SMITH, IAN F | Buy | 3,441 | — |
| 2026-03-09 | PERCEPTIVE, ADVISORS LLC | Buy | 8,912,655 | $5.61 |
Peer comparison
Smart narrative
Solid Biosciences LLC trades at $7.68. Our Smart Value Score of 31/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of -5.30, it sits in the distress.
Frequently asked questions
What is Solid Biosciences LLC's stock price?
Solid Biosciences LLC (SLDB) trades at $7.68, on a P/S of 3.6x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Solid Biosciences LLC overvalued?
Solid Biosciences LLC carries a Smart Value Score of 31/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Solid Biosciences LLC (SLDB)?
The 12-month analyst consensus target is $17.38, about 126.3% above the current $7.68. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Solid Biosciences LLC's Altman Z-Score is -5.30, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio3.65x
ROE-51.26%
Beta2.43
50D MA$7.36
200D MA$6.29
Shares out0.10B
Float0.05B
Short ratio—
Avg volume1.8M
Performance
1 week+15.12%
1 month+55.02%
3 months+36.18%
YTD+80.85%
1 year—
3 years—
5 years—